Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Vorbipiprant |
| Synonyms | |
| Therapy Description |
Vorbipiprant (CR6086) is an antagonist of the prostaglandin E2 receptor 4 (EP4) with potential immunomodulatory activity, and may enhance inhibition of tumor growth (PMID: 29490676, Cancer Res 2020;80(16 Suppl):Abstract nr 2208). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Vorbipiprant | CR 6086|CR-6086|CR6086 | Vorbipiprant (CR6086) is an antagonist of the prostaglandin E2 receptor 4 (EP4) with potential immunomodulatory activity, and may enhance inhibition of tumor growth (PMID: 29490676, Cancer Res 2020;80(16 Suppl):Abstract nr 2208). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05845450 | Phase II | Durvalumab Trastuzumab deruxtecan Panitumumab + Sotorasib Vorbipiprant Balstilimab + Botensilimab Nivolumab + Vorbipiprant Panitumumab Botensilimab | Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) | Recruiting | ITA | 0 |